Dulac Edward J III's Form 4 filing
Fate Therapeutics Inc (FATE) · filed Jan 30, 2024
- Accession no.
- 0000950170-24-008803
- Filed
- Jan 30, 2024
- Trade date
- Jan 29, 2024
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Checked
This filing lists 1 non-derivative transaction and 0 derivative transactions. Open-market sales total $9.24K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Dulac Edward J IIICIK 0001821530 | Officer (Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 29, 2024 | Common Stock | SSaleDisposed | −1,849 | $5.00 | −$9,245 | 103,926 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.